Sangamo Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Sangamo Therapeutics wird ein Gewinn- und Umsatzwachstum von 69.9% bzw. 49.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 71.8% pro Jahr wachsen soll.

Wichtige Informationen

57.5%

Wachstumsrate der Gewinne

63.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	46.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	22 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Aug 03

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Jul 23

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

Jun 19

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

May 29

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

May 14

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Mar 23

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Mar 16

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Mar 09

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Feb 02

Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Dec 04

Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Sep 11

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Aug 15

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Aug 08

Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

May 30

Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

May 13

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Apr 11

We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Dec 20

Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy

Sep 22

Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sep 18

Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead

Aug 31

Sangamo Therapeutics: Cheap, But Justifiably So

Aug 09

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

May 08

Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Apr 11

Sangamo Therapeutics: Lost In Transition From Lab To Clinic

Feb 24

Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?

Jan 10

Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December

Dec 03

We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow

Sep 22

Sangamo Therapeutics: Finding An Opportunity To Reload

Aug 21

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SGMO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	90	-61	-27	-17	6
12/31/2025	74	-52	-62	-52	7
12/31/2024	41	-108	-54	-49	7
6/30/2024	12	-250	-179	-173	N/A
3/31/2024	19	-328	-218	-207	N/A
12/31/2023	176	-258	-246	-225	N/A
9/30/2023	201	-250	-257	-231	N/A
6/30/2023	218	-199	-265	-238	N/A
3/31/2023	241	-127	-258	-231	N/A
12/31/2022	111	-192	-244	-224	N/A
9/30/2022	112	-178	-235	-219	N/A
6/30/2022	114	-172	-241	-225	N/A
3/31/2022	113	-176	-242	-224	N/A
12/31/2021	111	-178	-257	-233	N/A
9/30/2021	109	-181	-209	-185	N/A
6/30/2021	138	-135	-116	-92	N/A
3/31/2021	131	-124	101	120	N/A
12/31/2020	118	-121	155	170	N/A
9/30/2020	147	-76	136	153	N/A
6/30/2020	111	-102	64	81	N/A
3/31/2020	107	-96	-137	-118	N/A
12/31/2019	102	-95	-165	-144	N/A
9/30/2019	74	-118	-206	-164	N/A
6/30/2019	76	-104	-200	-152	N/A
3/31/2019	80	-90	-37	10	N/A
12/31/2018	84	-68	-7	37	N/A
9/30/2018	71	-63	44	60	N/A
6/30/2018	59	-62	64	72	N/A
3/31/2018	46	-58	N/A	6	N/A
12/31/2017	37	-55	N/A	11	N/A
9/30/2017	32	-51	N/A	16	N/A
6/30/2017	23	-58	N/A	14	N/A
3/31/2017	19	-72	N/A	-59	N/A
12/31/2016	19	-72	N/A	-66	N/A
9/30/2016	20	-76	N/A	-63	N/A
6/30/2016	25	-66	N/A	-60	N/A
3/31/2016	30	-52	N/A	-52	N/A
12/31/2015	40	-41	N/A	-34	N/A
9/30/2015	45	-31	N/A	-27	N/A
6/30/2015	49	-29	N/A	-19	N/A
3/31/2015	51	-24	N/A	-19	N/A
12/31/2014	46	-26	N/A	-6	N/A
9/30/2014	38	-30	N/A	-5	N/A
6/30/2014	31	-29	N/A	-3	N/A
3/31/2014	28	-27	N/A	0	N/A
12/31/2013	24	-27	N/A	-19	N/A
9/30/2013	26	-22	N/A	-18	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SGMO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SGMO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SGMO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SGMODie Einnahmen des Unternehmens (49.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: SGMODie Einnahmen des Unternehmens (49.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SGMO in 3 Jahren voraussichtlich hoch sein wird

Sangamo Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 32%

Consensus EPS estimates fall by 10%

Consensus revenue estimates fall by 13%

Consensus EPS estimates fall by 23%

Consensus revenue estimates fall by 11%

Price target decreased by 17% to US$6.12

Recent updates

Consensus revenue estimates increase by 32%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Sangamo Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New major risk - Share price stability

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

Consensus EPS estimates fall by 10%

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

New major risk - Financial position

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)

Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024

Sangamo Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Sangamo Therapeutics, Inc. Receives A Deficiency Notice from Nasdaq

Sangamo Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Sangamo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $24 million.

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Sangamo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $24 million.

Consensus revenue estimates fall by 13%

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sangamo Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial

Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Consensus EPS estimates fall by 23%

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023

Sangamo Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy

Now 24% undervalued after recent price drop

New minor risk - Market cap size

Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Consensus revenue estimates fall by 11%

Price target decreased by 17% to US$6.12

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Sangamo Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

Consensus revenue estimates fall by 12%

Sangamo Therapeutics, Inc. Appoints Lisa Rojkjaer as Chief Medical Officer

Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 22% to US$8.38

Consensus revenue estimates increase by 26%

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Price target decreased by 12% to US$11.24

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 15% to US$11.56

Price target decreased to US$13.11

Sangamo Therapeutics, Inc. Announces Directors Appointment

We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sangamo Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Sangamo Therapeutics, Inc. Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients

Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy

Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated A-Gal A Enzyme Activity in Five Longest Treated Patients

Sangamo Therapeutics, Inc Announces Executive Changes